Last reviewed · How we verify
NCT03339024
Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study
Phase 3 trial testing intranasal oxytocin spray in Alcoholism in 38 participants. Completed in 31 March 2019.
31 March 2019
Quick facts
| Lead sponsor | Norwegian University of Science and Technology |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 1 November 2017 |
| Primary completion | 31 March 2019 |
| Estimated completion | 31 March 2019 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- intranasal oxytocin spray
- intranasal spray without oxytocin
Conditions studied
- Alcoholism — all drugs for Alcoholism →
- Substance-Related Disorders — all drugs for Substance-Related Disorders →
Sponsor
Norwegian University of Science and Technology
Who can join
Adults 18 to 65, any sex, with Alcoholism or Substance-Related Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is an assessment of the long-term effect of oxytocin nasal spray on alcohol withdrawal and dependence in adults admitted for detoxification of alcohol after 60 days and 1 year. It is a follow-up study of a placebo-controlled randomized controlled study where subjects used oxytocin nasal spray during acute withdrawal and the following 4 weeks in an outpatient setting. Half of the participants have received oxytocin nasal spray, the other half placebo nasal spray (NCT02903251). (added March 2019: 24 patients were available for 1-year follow-up)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New idea to promote the clinical applications of stem cells or their extracellular vesicles in central nervous system disorders: Combining with intranasal delivery.
Li Y, Wu H, Jiang X, Dong Y, et al · · 2022 · cited 28× · PMID 35967290 · DOI 10.1016/j.apsb.2022.04.001
Verify or expand the search:
- PubMed search for NCT03339024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcoholism
Currently open trials in the same condition.
- NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
- NCT06493773 — Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial · NA · recruiting
- NCT07216872 — Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use · NA · recruiting
- NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
- NCT06415721 — Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder · NA · recruiting
Other Norwegian University of Science and Technology trials
Trials by the same sponsor.
- NCT07521891 — Socket-leg Interface Movements in Transtibial Amputees · NA · not yet recruiting
- NCT07463001 — Optimization and Testing Effectiveness of a Collaborative Intervention for School Attendance Problems in Norwegian Munic · NA · not yet recruiting
- NCT07422597 — Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prost · NA · recruiting
- NCT06558851 — The Effect of Systematic Endurance Training in Treatment of Women With Lipedema · NA · active not recruiting
- NCT06893874 — A Pragmatic Trial of Machine Prescription for Migraine · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03339024 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Norwegian University of Science and Technology
- Last refreshed: 19 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03339024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing